Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of lulizumab pegol versus placebo in active systemic lupus erythematosus
NL-OMON43900Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lulizumab pegol in systemic lupus erythematosus (SLE) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoint: BICLA response rate at Day 169. Started Jun 2016; status: active, not recruiting.
02
Drugs
lulizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON43900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43900.